BCM
ABEO icon

Bridgeway Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Bridgeway Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Buy
+50,000
New +$250K ﹤0.01% 1009

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridgeway Capital Management's ABEO Position: Q1 2026 in Review

Bridgeway Capital Management opened a new position in Abeona Therapeutics (ABEO) in Q1 2026: 50,000 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #1009 among its holdings.

108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Bridgeway Capital Management held 50,000 shares of Abeona Therapeutics worth $224K as of Q1 2026.
  • Abeona Therapeutics was a new Bridgeway Capital Management position in Q1 2026.
  • Abeona Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1009 holding.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.